|
Summary Information: AnaptysBio Inc. Common Stock NASDAQ:ANAB |
admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
__The following are links to various summary and news pages for __AnaptysBio Inc. Common Stock [ ANAB ]. __Note: Some Links might not have information for the company. |
|